InsiderTrades.com logo
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace   |   Ad
A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Markus Sieger net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Markus Sieger Biography and Net Worth

Director of Cyclo Therapeutics
Mr. Sieger is the President and CEO of Polpharma Group, a large regional pharmaceutical company, focused on Poland, Russia and other CEE markets, active in the development, production and sales of generic drugs and biosimilars. He holds supervisory board seats in public and private European companies. Mr. Sieger was for almost two decades a managing partner of an advisory group helping entrepreneurs in emerging markets to develop, finance, build and operate new businesses both operationally and strategically. Mr. Sieger managed successfully complex and strategic transactions with a focus on the pharmaceutical, food, media and engineering industries.

What is Markus Sieger's net worth?

The estimated net worth of Markus Sieger is at least $233,523.95 as of April 20th, 2023. Mr. Sieger owns 161,051 shares of Cyclo Therapeutics stock worth more than $233,524 as of May 1st. This net worth estimate does not reflect any other investments that Mr. Sieger may own. Learn More about Markus Sieger's net worth.

How do I contact Markus Sieger?

The corporate mailing address for Mr. Sieger and other Cyclo Therapeutics executives is 6714 NW 16TH STREET SUITE B, GAINSVILLE FL, 32653. Cyclo Therapeutics can also be reached via phone at (386) 418-8060 and via email at [email protected]. Learn More on Markus Sieger's contact information.

Has Markus Sieger been buying or selling shares of Cyclo Therapeutics?

Markus Sieger has not been actively trading shares of Cyclo Therapeutics during the last ninety days. Most recently, on Thursday, April 20th, Markus Sieger bought 59,881 shares of Cyclo Therapeutics stock. The stock was acquired at an average cost of $0.71 per share, with a total value of $42,515.51. Following the completion of the transaction, the director now directly owns 161,051 shares of the company's stock, valued at $114,346.21. Learn More on Markus Sieger's trading history.

Who are Cyclo Therapeutics' active insiders?

Cyclo Therapeutics' insider roster includes Joshua Fine (CFO), N. Fine (CEO), Sharon Hrynkow (Insider), Francis Ostronic (Director), Markus Sieger (Director), and Jeffrey Tate (COO). Learn More on Cyclo Therapeutics' active insiders.

Are insiders buying or selling shares of Cyclo Therapeutics?

During the last twelve months, Cyclo Therapeutics insiders bought shares 1 times. They purchased a total of 4,000,000 shares worth more than $5,000,000.00. The most recent insider tranaction occured on August, 1st when Major Shareholder Rafael Holdings, Inc. bought 4,000,000 shares worth more than $5,000,000.00. Insiders at Cyclo Therapeutics own 29.8% of the company. Learn More about insider trades at Cyclo Therapeutics.

Information on this page was last updated on 8/1/2023.

Markus Sieger Insider Trading History at Cyclo Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/20/2023Buy59,881$0.71$42,515.51161,051View SEC Filing Icon  
3/29/2022Buy10,000$2.73$27,300.00View SEC Filing Icon  
3/29/2021Buy10,000$8.10$81,000.0059,559View SEC Filing Icon  
3/29/2021Buy10,000$8.10$81,000.0067,614View SEC Filing Icon  
1/25/2021Buy7,799$6.30$49,133.70View SEC Filing Icon  
See Full Table

Markus Sieger Buying and Selling Activity at Cyclo Therapeutics

This chart shows Markus Sieger's buying and selling at Cyclo Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cyclo Therapeutics Company Overview

Cyclo Therapeutics logo
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
Read More

Today's Range

Now: $1.45
Low: $1.45
High: $1.57

50 Day Range

MA: $1.47
Low: $1.16
High: $1.75

2 Week Range

Now: $1.45
Low: $0.89
High: $2.57

Volume

29,137 shs

Average Volume

99,400 shs

Market Capitalization

$41.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace   |   Ad
A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...